IS:CIPLA Cipla Limited

Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India. It offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as women's health, cardiovascular, children's health, dermatology and cosmeceuticals, diabetes, HIV-AIDS, hepatitis, oncology, infectious diseases and critical care, malaria, neurosciences, ophthalmology, osteoporosis, respiratory, and urology. The company also provides veterinary products, including anti-infectives, anti-inflammatories, anti-thyroids, immunosuppressants, parasiticides, nutraceuticals, and feed additives for various animals, including equine and companion care, livestock, poultry, swine, and aqua products. In addition, it offers inhalation therapy devices comprising metered-dose inhalers, dry powder inhalers, nasal sprays, nebulizers, and inhalation accessory devices, as well as spacers and related devices. The company also exports its products to Africa, the Middle East, Latin America, the Asia Pacific, North America, Australia, New Zealand, Russia, and internationally. Cipla Limited was founded in 1935 and is based in Mumbai, India.

867.45 INR
As of 01/21/2022


Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Emerging markets
GICS sector:  Health Care
Industry:  Drug Manufacturers-General
Index country:  India
Country of incorporation:  India
IPO date:  05/12/2004
Stock exchange:    National Stock Exchange O
Exchange country:   India
Market cap:   700,145,795,072 INR
Current dividend yield:   0.57%
Sedol:      B011108

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy